ATE513051T1 - Präparation von rekombiniertem adenovirus-p53 zur tumorbehandlung - Google Patents

Präparation von rekombiniertem adenovirus-p53 zur tumorbehandlung

Info

Publication number
ATE513051T1
ATE513051T1 AT05700484T AT05700484T ATE513051T1 AT E513051 T1 ATE513051 T1 AT E513051T1 AT 05700484 T AT05700484 T AT 05700484T AT 05700484 T AT05700484 T AT 05700484T AT E513051 T1 ATE513051 T1 AT E513051T1
Authority
AT
Austria
Prior art keywords
adenovirus
preparation
tumor treatment
function
recombinant
Prior art date
Application number
AT05700484T
Other languages
English (en)
Inventor
Zhaohui Peng
Xiaozhi Zhang
Original Assignee
Peng Zhaohui C O Sibiono Co
Xiaozhi Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peng Zhaohui C O Sibiono Co, Xiaozhi Zhang filed Critical Peng Zhaohui C O Sibiono Co
Application granted granted Critical
Publication of ATE513051T1 publication Critical patent/ATE513051T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05700484T 2005-01-26 2005-01-26 Präparation von rekombiniertem adenovirus-p53 zur tumorbehandlung ATE513051T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/000111 WO2006079244A1 (fr) 2005-01-26 2005-01-26 Préparation d'adénovirus p53 recombiné dans le traitement d'une tumeur

Publications (1)

Publication Number Publication Date
ATE513051T1 true ATE513051T1 (de) 2011-07-15

Family

ID=36740014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05700484T ATE513051T1 (de) 2005-01-26 2005-01-26 Präparation von rekombiniertem adenovirus-p53 zur tumorbehandlung

Country Status (7)

Country Link
EP (1) EP1842921B1 (de)
JP (1) JP2008528522A (de)
AT (1) ATE513051T1 (de)
AU (1) AU2005326331B2 (de)
CA (1) CA2595874A1 (de)
TR (1) TR200705194T1 (de)
WO (1) WO2006079244A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5595973A (en) 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
CN1177057C (zh) * 2002-05-08 2004-11-24 彭朝晖 病毒载体与人肿瘤抑制基因的重组体及其应用

Also Published As

Publication number Publication date
EP1842921B1 (de) 2011-06-15
EP1842921A1 (de) 2007-10-10
CA2595874A1 (en) 2006-08-03
TR200705194T1 (tr) 2007-12-24
AU2005326331B2 (en) 2011-05-12
AU2005326331A1 (en) 2006-08-03
JP2008528522A (ja) 2008-07-31
WO2006079244A1 (fr) 2006-08-03
EP1842921A4 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
IL188101A0 (en) Use of hif 1-alpha modulators for treatment of cancer
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
DK1846406T5 (da) Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP2308885A3 (de) Neue Verbindungen und Anwendungen in der Therapie
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
EP2118123A4 (de) Stabilisierte p53-peptide und deren verwendungen
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EA200900623A1 (ru) Бициклические соединения и их применение в качестве противодиабетических средств
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
HK1155664A1 (en) Treatment of metastasized tumors
WO2006125815A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006125813A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
ATE513051T1 (de) Präparation von rekombiniertem adenovirus-p53 zur tumorbehandlung
DE602005019770D1 (de) Medizinische zusammensetzung zur behandlung von krebs oder diabetes
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties